Psoriatic Arthritis

Psoriatic Arthritis is a chronic inflammatory musculoskeletal condition associated with psoriasis, characterized by joint pain, stiffness, enthesitis, and progressive structural damage if left untreated. While psoriasis primarily manifests in the skin, the inflammatory process may extend to joints, tendons, and axial structures, making early recognition critical. As a multidisciplinary focus at every international Dermatology Conference, this session explores the intersection between dermatology and rheumatology, emphasizing early screening, immunologic pathways, and integrated care models. Closely associated with inflammatory arthritis in psoriasis, psoriatic arthritis requires coordinated management to prevent long-term disability.

The session begins by examining the immunopathogenesis shared between cutaneous psoriasis and joint inflammation. Cytokine pathways involving IL-17, IL-23, and TNF-alpha drive both epidermal hyperproliferation and synovial inflammation. Understanding these shared molecular mechanisms allows clinicians to select therapies that address both skin and joint manifestations simultaneously.

Clinical presentation varies widely. Some patients develop peripheral joint swelling affecting fingers and toes, while others experience axial spine involvement or enthesitis at tendon insertion points. Dactylitis, often described as “sausage digits,” serves as a hallmark sign. Participants will review screening tools that dermatologists can apply in routine practice to identify early joint symptoms.

Imaging techniques, including ultrasound and MRI, assist in detecting subclinical inflammation before irreversible joint damage occurs. The importance of timely rheumatology referral is emphasized to initiate disease-modifying therapy promptly.

Therapeutic strategies have evolved significantly. Biologic agents targeting TNF-alpha, IL-17, and IL-23 pathways offer effective control of both dermatologic and musculoskeletal symptoms. Small-molecule inhibitors further expand treatment options. Treatment selection considers disease severity, comorbidities, and patient-specific risk factors.

Long-term management requires ongoing monitoring for cardiovascular risk, metabolic syndrome, and mental health impact, as systemic inflammation may influence overall health. Patient education regarding symptom recognition and adherence supports sustained disease control.

By bridging dermatology and rheumatology expertise, this session empowers clinicians to detect psoriatic arthritis early and implement comprehensive, targeted interventions that preserve joint function and improve quality of life.